Novo Nordisk’s Twin Catalysts: India Green Light and Pipeline Data Test a Beaten-Down Stock

Novo Nordisk enters one of its most closely watched weeks of the year with two distinct narratives competing for investor attention. The Danish pharma group heads to the American Diabetes Association’s annual meeting in New Orleans starting Friday, where it will unveil full Phase 3 data for its experimental obesity candidate CagriSema. At the same time, it has secured a regulatory win thousands of miles away: India’s drug authority has approved Wegovy for adolescents aged 12 and over weighing more than 60 kilograms, opening a new demographic in a price-sensitive market.

The convergence of a major pipeline readout and a commercial expansion comes as Novo’s stock struggles to regain its footing. Shares closed at €39.05 on Friday, roughly 35% below last year’s level and nearly 45% off the record high of €70.13 hit in June 2025. The recovery from March’s trough of €30.48 stands at about 28%, but the stock remains 6.89% below its 200-day moving average and is down 12.59% year to date.

The India decision is more strategic than immediately material for revenue. Wegovy had been outsold in the injectable GLP-1 space there by Eli Lilly’s Mounjaro, but the younger-patient approval gives Novo a differentiated edge. Lilly lacks a similar adolescent label for Mounjaro in India. While the direct contribution from teenagers alone is unlikely to shift earnings significantly, the move signals how Novo intends to defend its GLP-1 franchise through broader indications and expanded access — crucial as pricing pressure and competition intensify globally.

The real test for the stock, however, lies in the data from the REIMAGINE Phase 3 study of CagriSema, a fixed-dose combination of cagrilintide and semaglutide. In one sub-study, patients saw their HbA1c drop by 1.91 percentage points and lost 14.2% of their body weight; 43% achieved at least 15% weight reduction. Novo submitted CagriSema to the FDA in December 2025, with a decision expected in the fourth quarter of this year and a potential launch in early 2027. The ADA presentation will be the last major public glimpse before the agency’s verdict. The company is also scheduled to present interim data on Zenagamtide, another injectable GLP-1/amylin candidate, and will hold an R&D investor event on June 7.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Even if the pipeline delivers, Novo faces a more crowded competitive field than it did a year ago. In April, Eli Lilly gained FDA approval for its oral weight-loss pill Foundayo, ending Novo’s brief monopoly on an oral obesity therapy in the US. That development, alongside broader formulary and pricing headwinds, has kept analysts cautious. Jefferies and Deutsche Bank both maintain “Hold” ratings on the stock. Jefferies set a price target of 270 Danish kroner, below the recent Copenhagen close of 292.95 DKK. Citi lifted its target to 290 DKK but still rates the shares neutral.

The company’s multi-billion-dollar buyback programme provides some floor. Between February and May 22, Novo had repurchased 17,049,028 B-shares at an average price of 262.22 DKK, spending 4.47 billion DKK out of a total framework of up to 15 billion DKK running through early 2027. The treasury now holds 34,234,329 B-shares, representing 0.8% of share capital. The buybacks underpin capital returns during a period of uncertainty, but they do not substitute for organic growth.

On the medical front, Novo also published results from the real-world POSEIDON study, encompassing 18,904 patients across 18 countries. It found that cardiovascular inflammation remains widespread despite standard therapy, with 40% of those suffering from both atherosclerotic cardiovascular disease and chronic kidney disease showing hsCRP levels of at least 2 mg/L. The findings reinforce the broader theme of unmet need in cardiometabolic disease, a backdrop that supports Novo’s pipeline ambitions even as near-term earnings face pressure.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

That pressure is reflected in the company’s own guidance. Novo expects currency-adjusted declines of 4% to 12% in both revenue and operating profit for 2026. Adjusted revenue in the first quarter, stripping out a 340B-related distortion, fell 4% in constant currencies, while obesity-product sales rose 22%. The tension is clear: strong volume demand is being eroded by lower realised prices and margin compression.

This week’s ADA conference will test whether clinical data can rekindle confidence in the pipeline. If CagriSema meets expectations, the narrative could shift back toward long-term growth. A miss would amplify the existing scepticism. For now, the stock remains a story of two halves — compelling medical science and a tough commercial environment — with the next chapter beginning in New Orleans.

Ad

Novo Nordisk Stock: New Analysis - 30 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69448025 |